仅MRI可见的乳腺癌比常规影像可识别的乳腺癌侵袭性更低
该回顾性单中心观察研究纳入2017年1月至2022年12月间接受乳腺MRI、至少一个病灶主要由MRI发现并经组织学证实为恶性的435例患者,比较仅MRI可见病灶与靶向二次超声(SLUS)可识别病灶的亚型差异。仅MRI组占34.02%(148例),病灶更小(10 mm vs 20 mm)、多为T1期(66.9%)、纯导管原位癌比例更高(30.4% vs 5.2%)、Ki-67中位数更低(10 vs 20),SLUS检出组腋窝转移比例更高。结论为仅MRI可见病灶在组织学和免疫组化上侵袭性更低、分期更低。
要点
- 仅MRI可见病灶占34.02%(148/435),SLUS可识别病灶占65.98%(287/435)。
- 仅MRI组病灶更小(10 mm vs 20 mm),T1期占66.9%,纯导管原位癌占30.4% vs 5.2%。
- SLUS检出组镜下腋窝转移4.9% vs 3.4%、宏观腋窝转移26.8% vs 7.4%,均P < 0.001。
核心结论
- 仅MRI可见病灶在组织学和免疫组化上较SLUS检出病灶呈现更低侵袭性模式,分期更低,作者认为这提供了更早治疗机会的潜力,因为病灶在变得更具侵袭性和破坏性之前即可在MRI上显示。
研究设计与样本
- 回顾性单中心观察研究,纳入2017年1月至2022年12月间接受乳腺MRI检查、至少一个病灶主要由MRI发现并经组织学证实为恶性的435例患者,比较仅MRI可见组(n=148)与SLUS检出组(n=287)的人口学特征、病灶类型(肿块或非肿块)、MRI评估病灶大小(mm)、组织学诊断、分期、免疫组化(ER、PR、HER-2、Ki-67)及淋巴结状态。
诊断标准与关键数值
- 仅MRI组病灶大小10 mm vs SLUS检出组20 mm,仅MRI组更小。
- 仅MRI组纯导管原位癌占30.4% vs SLUS检出组5.2%,仅MRI组更高。
- 仅MRI组Ki-67中位值10 vs SLUS检出组20,仅MRI组更低。
- 仅MRI组T1期占66.9%。
- SLUS检出组镜下腋窝转移4.9% vs 仅MRI组3.4%、宏观腋窝转移26.8% vs 7.4%,均P < 0.001。
临床应用与阅片要点
- 原文结论认为仅MRI可见病灶生物学上侵袭性更低、分期更低,因其在变得更具侵袭性和破坏性之前即可在MRI上显示,提供更早治疗机会的潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Magnetic resonance imaging (MRI) has a superior sensitivity for the diagnosis of breast cancer, leading to lesions primarily detected by MRI. Some of these lesions cannot be identified by targeted second-look ultrasound (SLUS) examinations and are thus referred to as MRI-only lesions. We hypothesize that biologically more aggressive cancers lead to more distinct tissue damage improving visibility on SLUS.
OBJECTIVE: To investigate whether there are differences in cancer subtypes between MRI-only and SLUS-detected malignant lesions.
METHODS: This retrospective single-center observational study evaluated 435 patients who received breast MRI examinations between January 2017 and December 2022, with at least one lesion primarily detected on MRI and histologically confirmed as malignant. Demographic characteristics, lesion type (mass or non-mass), MRI-assessed lesion size (mm), histological diagnosis, stage, immunohistochemical analysis (ER, PR, HER-2, Ki-67), and lymph node status were assessed and compared between MRI-only and SLUS-detected.
RESULTS: Among 435 patients (mean age of 57.4 ± 13.3), 34.02 % (n = 148) were in the MRI-only group, while the remaining 65.98 % (n = 287) were identified by SLUS. MRI-only cases were significantly smaller in size (10 mm vs 20 mm), mostly staged as T1 (66.9 %) and showed features associated with less biological aggressiveness (higher pure ductal carcinoma in situ rates: 30.4 % vs 5.2 %; lower Ki-67, median values: 10 vs 20) compared to SLUS-detected cases (P < 0.001). SLUS-detected cancers had higher ratios of microscopic (4.9 % vs 3.4 %) and macroscopic axillary metastasis (26.8 % vs 7.4 %) compared to MRI-only lesions (P < 0.001).
CONCLUSION: MRI-only lesions presented histologically and immunohistochemically with less aggressive patterns compared to those detected via SLUS. Clinic Impact: Our data provide evidence that MRI-only lesions are biologically less aggressive and of lower stage, offering the potential of earlier treatment chance since they are visible on MRI before becoming more aggressive and destructive.
引用
- Baykara Ulusan M, Ferrara F, Meltem E, et al. MRI-only breast cancers are less aggressive than cancers identifiable on conventional imaging. Eur J Radiol. 2024. PMID: 39427496. doi:10.1016/j.ejrad.2024.111781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。